Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US
Semaglutide was associated with 40% to 70% reduced risks of first-time AD diagnosis in T2DM patients compared to other antidiabetic medications, including other GLP-1RAs. Semaglutide was associated with significantly lower AD-related medication prescriptions. Similar reductions were seen across obesity status, gender, and age groups. Our findings provide real-world evidence supporting the potential clinical benefits of semaglutide in mitigating AD initiation and development in patients with T2DM. These findings support further clinical trials to assess semaglutide's potential in delaying or preventing AD.
Authors
- Nora D. Volkow (ORCID: https://orcid.org/0000-0001-6668-0908)
- Pamela B. Davis (ORCID: https://orcid.org/0000-0002-7113-5338)
- Rong Xu (ORCID: https://orcid.org/0000-0003-3127-4795)
- Xin Qi (ORCID: https://orcid.org/0000-0002-9578-3890)
- David C. Kaelber (ORCID: https://orcid.org/0000-0001-7855-9515)
- George Perry (ORCID: https://orcid.org/0000-0002-6547-0172)
- QuangQiu Wang
- William Yang Wang (ORCID: https://orcid.org/0000-0002-0878-1257)
- Mark E. Gurney (ORCID: https://orcid.org/0000-0003-4901-3083)
Institutions
- MetroHealth (US)
- National Institutes of Health (US)
- National Institute on Drug Abuse (US)
- University School (US)
- The University of Texas at San Antonio (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1002/alz.14313
- Citations
- 125
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 44.71
Funders
- Case Western Reserve University
- National Institute on Aging
- National Center for Advancing Translational Sciences